Danaparoid
- Atc Codes:B01AB09
- CAS Codes:57459-72-0#54328-33-5#39455-18-0#12678-07-8
- PHARMGKB ID:57459-72-0#54328-33-5#39455-18-0#12678-07-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Orgaran; Belgium: Orgaran; Finland: Orgaran; France: Orgaran; Germany: Orgaran; Greece: Orgaran; Ireland: Orgaran; Luxembourg: Orgaran; Netherlands: Orgaran; Sweden: Orgaran; UK: Orgaran.
North America
Canada: Orgaran.
Asia
Japan: Orgaran.
Drug combinations
Chemistry
Danaparoid Sodium: Danaparoid is a low molecular weight heparinoid, a mixture of the sodium salts of heparan sulfate (approx. 84%), dermatan sulfate (approx. 12%), and chondroitin sulfate (approx. 4%). It is derived from porcine intestinal mucosa. Heparan Sulfate: Heparitin, sulfate, sodium salt. CAS-57459-72-0. Dermatan Sulfate: Dermatan, 4-(hydrogen sulfate), sodium salt. CAS-54328-33-5. Chondroitin 4-sulfate: Chondroitin, 4-(hydrogen sulfate), sodium salt. CAS-39455-18-0. Chondroitin 6-sulfate: Chondroitin, 6-(hydrogen sulfate), sodium salt. CAS-12678-07-8 (1992).
Pharmacologic Category
Antithrombotic Agents; Anticoagulants; Heparins. (ATC-Code: B01AB09).
Mechanism of action
Prevents fibrin formation in coagulation pathway via thrombin generation inhibition by anti-Xa and anti-IIa effects.
Therapeutic use
Prevention of postoperative deep vein thrombosis following elective hip replacement surgery.
Pregnancy and lactiation implications
Compatible with lactation.
Unlabeled use
Systemic anticoagulation for heparin-induced thrombocytopenia.
Contraindications
Hypersensitivity to danaparoid. Thrombocytopenia. Hypersensitivity to pork products or sulfites. Hemorrhagic diathesis. Not for I.M. or I.V. use.
Warnings and precautions
Patients with certain risk factors may be at risk of bleeding. May cause hyperkalemia by affecting aldosterone. Caution in hypersensitivity to methylparaben or propylparaben, history of heparin-induced thrombocytopenia or severe renal failure. Contains sodium sulfite, which may cause allergic-type reactions (frequently seen in asthmatics). Not convertible to other low molecular weight heparins. Risk of spinal or epidural hematoma in recent or anticipated neuraxial anesthesia.